Shun Yu-Ting, Lai Hsien-Yung, Chuang Yi-Ting, Lin Hsuen-Fu
Department of Pharmacy, Mennonite Christian Hospital, Hualien.
Department of Anesthesiology, Mennonite Christian Hospital, Hualien.
Clin Med Insights Case Rep. 2023 Jan 29;16:11795476221150354. doi: 10.1177/11795476221150354. eCollection 2023.
Irinotecan, a topoisomerase I inhibitor, is commonly used in the treatment of advanced colorectal cancer. Its adverse effects include delay diarrhea, severe myelosuppression, and cholinergic-like symptoms. Though 2 cases of irinotecan-induced muscle twitching were reported but the successful treatment of this adverse event still not shown. We present a 24-year-old female patient with advanced colorectal cancer received bevacizumab and FOLFIRI (irinotecan + calcium leucovorin + 5-fluorouracil) treatment. Her right pectoralis major muscle presented with involuntary muscle twitching during the infusion of irinotecan at the sixth cycle of chemotherapy. The muscle twitching was slowly dissipated about 4 hours after the halted of irinotecan infusion. Then lorazepam 2 mg iv was injected before administration of irinotecan in an attempt to prevent the muscle twitching in the seventh cycle of chemotherapy. The patient did not report further muscle twitching. After that, lorazepam was routine administered before each cycle of FOLFIRI regiment. No any muscle twitching was observed after the use of lorazepam. This case provides valuable insight that muscle twitching can occur as rare irinotecan-related adverse effect. Benzodiazepine agonists, such as lorazepam, is the potential treatment of choice.
伊立替康是一种拓扑异构酶I抑制剂,常用于治疗晚期结直肠癌。其不良反应包括延迟性腹泻、严重骨髓抑制和类胆碱能症状。虽然有2例伊立替康引起肌肉抽搐的报道,但该不良事件的成功治疗方法仍未明确。我们报告1例24岁晚期结直肠癌女性患者,接受了贝伐单抗和FOLFIRI(伊立替康+亚叶酸钙+5-氟尿嘧啶)治疗。在化疗第6周期输注伊立替康期间,其右胸大肌出现不自主肌肉抽搐。伊立替康输注停止约4小时后,肌肉抽搐逐渐缓解。随后在第7周期化疗输注伊立替康前静脉注射2mg劳拉西泮,试图预防肌肉抽搐。患者未再报告肌肉抽搐情况。此后,在每个FOLFIRI方案化疗周期前常规使用劳拉西泮。使用劳拉西泮后未观察到任何肌肉抽搐。该病例提供了有价值的见解,即肌肉抽搐可能是伊立替康罕见的相关不良反应。苯二氮䓬类激动剂,如劳拉西泮,是潜在的治疗选择。